Many clinical studies have shown that everolimus reduces the risk of cytomegalovirus (CMV) infection in transplant recipients because CMV replication is dependent on mTOR activity.2 However, CMV-related infections are encountered occasionally in patients taking everolimus. Here, MTOR is linked to cytomegalovirus infection.